Data-sharing website may speed the response to new illegal drugs

The drug overdose epidemic currently gripping the nation is so tenacious in part because it's being driven by fentanyl, a synthetic opioid that comes in many forms. Each form has a slightly different chemical structure, and clandestine chemists are constantly cooking up new ones. From a law-enforcement perspective, this makes fentanyl a moving target and very difficult to control.

To help with this situation, scientists at the National Institute of Standards and Technology (NIST), the German Federal Criminal Police Office (the Bundeskriminalamt, or BKA) and the U.S. Drug Enforcement Agency have launched a website where forensic chemists can share data on new drug variants, also called drug analogs. Described in Forensic Chemistry, the NPS Data Hub (NPS stands for Novel Psychoactive Substances) includes the chemical structures of drug analogs and their chemical signatures, which are the keys to identifying them in the lab.

Being able to identify drugs quickly is critical. "If people start overdosing and dying from a new drug analog, authorities need to identify it as quickly as possible," said Aaron Urbas, the NIST research chemist who led the project. "If you want to focus your resources effectively, you need to know what you're looking for."

The goal of the NPS Data Hub is to get drug identification data to forensic chemists more quickly. In addition to data on synthetic opioids such as fentanyl, the Data Hub is also intended to cover synthetic cannabinoids (aka synthetic marijuana), synthetic cathinones (aka bath salts), amphetamines and other dangerous drugs.

Underground chemists create new analogs in part to boost drug potency, with some fentanyl analogs being thousands of times stronger than heroin. This increases the risk to users, who may not know exactly what they're consuming. New analogs also allow the manufacturers to stay one step ahead of the law.

When drug evidence is seized, forensic chemists will often try to identify it using an instrument such as a mass spectrometer, which generates a unique barcode-like pattern - a sort of chemical signature - for the compound in question. They will then search law enforcement databases for a known compound with the same signature.

If the drug is new, the signature won't be recognized, and a much more complex analysis will be needed to identify the substance and determine its chemical structure. Few labs have that capability, so the drug may need to be sent to a more advanced facility. The whole process can take six months or more, including quality control to ensure the accuracy of the chemical structure and other data.

After that process is complete, the new drug and its chemical signature are added to law enforcement databases so that it can be identified more easily next time around. "

We want to shorten the time lag between discovery of a new drug and the distribution of the data needed to identify it," Urbas said.

The NPS Data Hub aims to shorten that time lag by making it easier for experts to collaborate. For instance, a chemist from one lab can analyze a new drug and upload a proposed chemical structure and supporting data to the Data Hub. Then a second chemist from a different lab can review the data and confirm the proposed structure or suggest a new one.

"These people have very rare expertise," said NIST senior policy advisor Jayne Morrow. "The Data Hub brings these experts together and provides a forum where they can discuss what they're seeing in real time. There haven't been great ways to do that before, and it's really needed."

Only labs with sufficient capabilities can propose and confirm chemical structures. But other labs, including smaller state and local labs, can use that data.

In addition to the collaboration mechanism, the NPS Data Hub differs from existing drug databases in two ways. First, many databases only include chemical signatures based on commonly used techniques such as mass spectrometry. The NPS Data Hub permits sharing of analytical data from any technique, including Nuclear Magnetic Resonance (NMR), Raman spectroscopy, and others that, though less common, can be useful for differentiating closely related compounds.

Second, in commonly used drug databases such as the one maintained by the Scientific Working Group for the Analysis of Seized Drugs (SWGDRUG), the information is highly vetted for quality control. That makes SWGDRUG data authoritative, but the vetting takes months to complete. The NPS Data Hub is meant to be less authoritative but updated more frequently.

"The Data Hub can contain both curated and preliminary data, so you wouldn't necessarily use it to produce courtroom evidence," Urbas said. "But for tracking the emergence of new drug analogs, even preliminary data can make a huge difference."

Aaron Urbas, Torsten Schoenberger, Charlotte Corbett, Katrice Lippa, Felix Rudolphi, Wolfgang Robien.
NPS Data Hub: A web-based community driven analytical data repository for new psychoactive substances.
Forensic Chemistry, Volume 9, June 2018, Pages 76-81. doi: 10.1016/j.forc.2018.05.003.

Most Popular Now

How SARS-CoV-2 mutates to escape antibody binding

In a recurring pattern of evolution, SARS-CoV-2 evades immune responses by selectively deleting small bits of its genetic sequence, according to new research from the Uni...

Early functional SARS-COV-2 specific T cell respon…

Humoral and cellular adaptive immunity are two immune mechanisms that act against pathogens. Humoral immunity is mediated by antibodies, while cellular immunity does not ...

Anticancer drug may improve outcome for severe COV…

Treating severe COVID-19 patients with the anticancer drug bevacizumab may reduce mortality and speed up recovery, according to a small clinical study in Italy and China ...

One dose of COVID-19 vaccine provokes strong immun…

Although clinical trial data are encouraging, real-world evidence with regard to the COVID-19 vaccine remains scarce. In particular, response to the vaccine among those p...

Johnson & Johnson announces submission of appl…

Johnson & Johnson (NYSE: JNJ) (the Company) announced that Janssen Biotech, Inc., has submitted an application to the U.S. Food and Drug Administration (FDA) requesting E...

CureVac initiates rolling submission with European…

CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today annou...

Pfizer and BioNTech publish data from in vitro stu…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the publication in Nature Medicine of data from in vitro studies that demonstrate that sera from in...

COVID-19 Vaccine AstraZeneca recommended for use i…

AstraZeneca's COVID-19 vaccine has been recommended for conditional marketing authorisation (CMA) in the European Union (EU) for active immunisation to prevent COVID-19 c...

Roche announces the upcoming launch of the SARS-Co…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced it has obtained the CE mark for its new SARS-CoV-2 Rapid Antigen Test Nasal. The test will be available in countries acceptin...

Sinovac receives conditional marketing authorizati…

Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced that the China National Medical Produ...

A machine-learning approach to finding treatment o…

When the COVID-19 pandemic struck in early 2020, doctors and researchers rushed to find effective treatments. There was little time to spare. "Making new drugs takes fore...

Bayer to manufacture mRNA vaccine in Germany

In a joint press briefing today together with German Health Minister Jens Spahn, Minister-President of North Rhine-Westphalia, Armin Laschet, and Chief Executive Officer ...